Journal of Neurology

, Volume 261, Issue 9, pp 1684–1690 | Cite as

Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis

  • Thomas HundsbergerEmail author
  • Kai M. Rösler
  • Oliver Findling
Original Communication


Enzyme replacement therapy (ERT) with recombinant human alglucosidase alfa (rhGAA) in late-onset Pompe disease is moderately effective. Little is known about the clinical course after treatment termination and the resumption of ERT. In Switzerland, rhGAA therapy for Pompe disease was temporarily withdrawn after the federal court judged that the treatment costs were greatly out of proportion compared to the benefits. Re-treatment was initiated after the therapy was finally licensed. We retrospectively analysed seven Pompe patients, who underwent cessation and resumption of ERT (median age 43 years). The delay from first symptoms to final diagnosis ranged from 4 to 20 years. The demographics, clinical characteristics, assessments with the 6-min walking test (6-MWT), the predicted forced vital capacity (FVC) and muscle strength were analysed. Before initiation of ERT, all patients suffered from proximal muscle weakness of the lower limbs; one was wheelchair-bound and two patients received night-time non-invasive ventilation. Initial treatment stabilised respiratory function in most patients and improved their walking performance. After treatment cessation, upright FVC declined in most and the 6-MWT declined in all patients. Two patients needed additional non-invasive ventilatory support. Twelve months after resuming ERT, the respiratory and walking capacity improved again in most patients. However, aside for one patient, none of the patients reached the same level of respiratory function or distance walked in 6 min, as at the time of ERT withdrawal. We conclude that cessation of ERT in Pompe disease causes a decline in clinical function and should be avoided. Resuming treatment only partially recovers respiratory function and walking capacity.


Muscle disease Metabolic disease Pompe disease GSD II Enzyme replacement therapy 



TH thanks Barbara Tettenborn for continuous support for treating patients with Pompe disease.

Conflicts of interest

TH and KMR served as consultants, received funding for travel expenses and received honoraria from serving on a scientific advisory board from Genzyme, Switzerland. OF received funding for trips and received honoraria from serving on a scientific advisory board from Genzyme, Switzerland.

Ethical standards

The local ethics committee approved this retrospective analysis.


  1. 1.
    ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRefGoogle Scholar
  2. 2.
    Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, Moggio M, Filosto M, Sette E, Crescimanno G, Tonin P, Parini R, Morandi L, Marrosu G, Greco G, Musumeci O, Di IG, Siciliano G, Donati MA, Carubbi F, Ermani M, Mongini T, Toscano A (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259:952–958CrossRefPubMedGoogle Scholar
  3. 3.
    Bembi B, Cerini E, Danesino C, Donati MA, Gasperini S, Morandi L, Musumeci O, Parenti G, Ravaglia S, Seidita F, Toscano A, Vianello A (2008) Management and treatment of glycogenosis type II. Neurology 71:S12–S36CrossRefPubMedGoogle Scholar
  4. 4.
    Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R, Rigoldi M, Moglia A, Costa A, Carlucci A, Danesino C, Pittis MG, Dardis A, Ravaglia S (2010) Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 33:727–735CrossRefPubMedGoogle Scholar
  5. 5.
    Chetta A, Zanini A, Pisi G, Aiello M, Tzani P, Neri M, Olivieri D (2006) Reference values for the 6-min walk test in healthy subjects 20–50 years old. Respir Med 100:1573–1578CrossRefPubMedGoogle Scholar
  6. 6.
    de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber CG, Verschuuren JJ, Kruijshaar ME, Reuser AJ, van Doorn PA, van der Ploeg AT (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 7:73PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Hundsberger T, Rohrbach M, Kern L, Rosler KM (2013) Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease. J Neurol 260:2279–2285CrossRefPubMedGoogle Scholar
  8. 8.
    Jurecka A, Zuberuber Z, Opoka-Winiarska V, Wegrzyn G, Tylki-Szymanska A (2012) Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature. Mol Genet Metab 107:508–512CrossRefPubMedGoogle Scholar
  9. 9.
    Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE (2007) Recombinant human acid a-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109CrossRefPubMedGoogle Scholar
  10. 10.
    Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ (2012) The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 160C:59–68CrossRefPubMedGoogle Scholar
  11. 11.
    Lachmann R, Schoser B (2013) The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis 8:160–172PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Laloui K, Wary C, Carlier RY, Hogrel JY, Caillaud C, Laforet P (2011) Making diagnosis of Pompe disease at a presymptomatic stage: to treat or not to treat? Neurology 77:594–595CrossRefPubMedGoogle Scholar
  13. 13.
    Lin DS, Chiang MF, Ho CS, Hsiao CD, Lin CY, Wang NL, Chuang CK, Huang YW, Chang PC, Liu HL (2013) Low-frequency enzyme replacement therapy in late-onset Pompe disease. Muscle Nerve 47:612–613CrossRefPubMedGoogle Scholar
  14. 14.
    Raben N, Wong A, Ralston E, Myerowitz R (2012) Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet 160:13–21PubMedCentralCrossRefGoogle Scholar
  15. 15.
    Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, Muller-Felber W, Glocker FX, Spranger M, Deschauer M (2012) 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 35:837–845CrossRefPubMedGoogle Scholar
  16. 16.
    Schoser B, Hill V, Raben N (2008) Therapeutic approaches in glycogen storage disease type II/Pompe disease. Neurotherapeutics 5:569–578PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Simoens S, Cassiman D, Dooms M, Picavet E (2012) Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs 72:1437–1443CrossRefPubMedGoogle Scholar
  18. 18.
    Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S, Brejova A, Hilz M, Reiners K, Muller-Felber W, Mengel E, Spranger M, Schoser B (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91–97CrossRefPubMedGoogle Scholar
  19. 19.
    Thurberg BL, Lynch MC, Vaccaro C, Afonso K, Tsai AC, Bossen E, Kishnani PS, O’Callaghan M (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86:1208–1220CrossRefPubMedGoogle Scholar
  20. 20.
    Toscano A, Schoser B (2013) Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 260:951–959CrossRefPubMedGoogle Scholar
  21. 21.
    van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, Van HH, van Diggelen OP, Boer M, Kroos MA, van Doorn PA, Van der Voort E, Sibbles B, Van Corven EJ, Brakenhoff JP, Van Hove J, Smeitink JA, de Jong G, Reuser AJ, van der Ploeg AT (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448–e457CrossRefPubMedGoogle Scholar
  22. 22.
    van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, de Visse M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber KG, Verschuuren JJ, Reuser AJ, van der Ploeg AT, van Doorn PA (2012) Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 7:88PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, van der Ploeg AT, van Doorn PA, Wokke JH (2009) Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 19:113–117CrossRefPubMedGoogle Scholar
  24. 24.
    van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406CrossRefPubMedGoogle Scholar
  25. 25.
    van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372:1342–1353CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Thomas Hundsberger
    • 1
    Email author
  • Kai M. Rösler
    • 2
  • Oliver Findling
    • 2
  1. 1.Department of NeurologyCantonal Hospital St. GallenSt. GallenSwitzerland
  2. 2.Department of NeurologyInselspital, University Hospital Bern and University of BernBernSwitzerland

Personalised recommendations